| |
Pediatric and Adolescent Treatment Concepts
- J. Friedberg
- C. Mauz-Körholz
Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective
Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective
Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization
Oral presentation of selected abstracts
|
|
Special Situations & Cases
Treatment Approaches in Ressource Constraint Settings
HL Richter Transformation
- O. Al-Sawaf
- M. Hartmann
- M. Hertzberg
|
|
|
|
|
|
Seminars and
Workshops (parallel sessions)
Workshop:
Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma
(Separate registration required)
- S. Barrington
- S. Borchmann
- C. Kobe
- W. Plattel
- D. Rossi
Workshop:
EHA-LYG / GHSG Joint Session “Emerging Therapeutic Concepts in B-Cell Lymphomas”
|
|
|
|
|
|
|
|
|
|
NLPHL: HL, NHL or something else?
First-line treatment of NLPHL with HL-directed approaches
Treatment of NLPHL with NHL-directed approaches
|
|
|
|
|
|
|
|
|
|
Biology & Microenvironment
Pathogenesis of HL
Multimodal characterization of cHL
Oral presentation of selected abstracts
|
|
|
|
|
|
|
|
|
|
Living Beyond Lymphoma
Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)
Starting Living beyond Lymphoma with HL diagnosis
Participation in and (cost-)effectiveness of the Dutch HL survivorship care program
Oral presentation of selected abstracts
|
|
|
|
|
|
|
|
|
|
Limited Stages
IIntro: Treatment concepts in early-stage HL
Viewpoint: Systemic Therapy only in the future?
Viewpoint: CMT (is it there to stay?)
Oral presentation of selected abstracts
|
|
|
|
|
|
|
Satellite Symposium 2
|
|
|
|
|
|
Relapsed & Refractory HL
Updated approach to second-line treatment
Emerging strategies to overcome anti-PD1 resistance
Implementing raditoherapeutic concepts in rrHL care
Oral presentation of selected abstracts
|
|
|
|
|
| |
|
|
|
|
Satellite Symposium 1
|
|
|
|
|
|
|
|
|
|
Older Patients
Implementing Frailty Assessment for Treatment Guidance in HL
Optimal Use of Targeted Agents to Address Unmet Need in Older HL
Oral presentation of selected abstracts
|
|
Closing remarks
- R. Advani
- S. Barrington
- S. Borchmann
- C. Kobe
- W. Plattel
WS Report
- S. Barrington
- S. Borchmann
- C. Kobe
- W. Plattel
- D. Rossi
Best of ISHL13
|
|
|
|
|
|
|
|
|
|
|
|
Opening and Award Ceremony
Keynote Lecture
|
|
|
|
|
|
|
|
|
|
|
|
Satellite Symposium 3
|
|
|
|
|
|
|
|
|
|
|
Poster Session & Welcome Reception
|
|
|
|
|
|
|
|
|
|
Advanced Stages
Individualized treatment de-escalation improves overall outcomes
Immune-chemotherapy overcomes the need for individualization
Oral presentation of selected abstracts
|
|
|
|
|
| |
|
|
|
| |
|
|
|